亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

医学 乳腺癌 骨痛 外科 化疗 骨质疏松症 骨病 骨转移 癌症 内科学
作者
PierFranco Conte,Jean Latreille,L. Mauriac,Federico Calabresi,Roberto Boettier dos Santos,Daniela Duarte Campos,Jacques M Bonneterre,Guido Francini,J. Ford
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:14 (9): 2552-2559 被引量:279
标识
DOI:10.1200/jco.1996.14.9.2552
摘要

PURPOSE: Bone metastases are a major cause of morbidity in breast cancer, resulting in complications that include pain, loss of mobility, pathologic fracture, and tumor-induced hypercalcemia (TIH). Inhibition of osteoclast-mediated bone destruction using bisphosphonates represents a promising new management approach. PATIENTS AND METHODS: Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients). Whenever possible, treatment continued until progression of disease (PD) in bone appeared on radiographs or bone scan. Time to PD in bone and pain reduction according to a self-assessment six-point scale were selected as primary end points. PD in bone was verified during extramural review (EMR) of all imaging studies by blinded observers, and these data were used as the main efficacy criterion. Analgesic intake, World Health Organization (WHO) performance status, and complications of bone metastases (radiotherapy, TIH, fractures, orthopedic surgery) were also compared in the two groups. RESULTS AND CONCLUSION: At EMR, median time to PD in bone was increased by 48% in patients who received pamidronate (249 v 168 days; P = .02, Wilcoxon test). Marked pain relief, defined as a two-point decrease lasting for > or = 6 weeks, was reported by 44% of pamidronate patients and by 30% of controls (P = .025, chi 2 test). The infusions (median, nine per patient; range, 0 to 39) were well tolerated, with no major toxicities reported. Pamidronate by repeated infusion can significantly slow the progression of bone metastases and reduce attendant morbidity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
3秒前
159357发布了新的文献求助30
4秒前
可爱馒头完成签到,获得积分10
4秒前
4秒前
6秒前
传奇3的应助被Flynn采纳,获得10
7秒前
yangzai完成签到 ,获得积分0
8秒前
9秒前
李华完成签到,获得积分10
10秒前
10秒前
欣喜的若山完成签到 ,获得积分10
10秒前
黄天完成签到 ,获得积分10
11秒前
小叶子完成签到 ,获得积分10
12秒前
llqq完成签到,获得积分10
12秒前
洪亮完成签到,获得积分10
13秒前
李华发布了新的文献求助10
14秒前
15秒前
15秒前
15秒前
林诗萍完成签到 ,获得积分10
16秒前
Flynn发布了新的文献求助10
20秒前
清汐完成签到 ,获得积分10
20秒前
阿腾发布了新的文献求助10
21秒前
25秒前
loii的应助被务实的小凡采纳,获得50
25秒前
小马甲的应助被阿腾采纳,获得10
26秒前
28秒前
28秒前
Flynn完成签到,获得积分10
29秒前
陈鑫龙完成签到 ,获得积分10
29秒前
30秒前
liugaoleng完成签到 ,获得积分10
32秒前
32秒前
33秒前
巨型肥猫发布了新的文献求助10
33秒前
111发布了新的文献求助10
34秒前
瑩火虫完成签到 ,获得积分10
35秒前
Saturday完成签到,获得积分10
36秒前
tt完成签到 ,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778